Is the dose of dabigatran really more predictable than warfarin?

British Journal of Clinical Pharmacology

Volumn 76, Issue 6, 2013, Pages 997-998

  Wright, Daniel F B ^a   Al Sallami, Hesham S ^a   Duffull, Stephen B ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; DABIGATRAN ETEXILATE; WARFARIN;

ANTICOAGULATION; AREA UNDER THE CURVE; DOSE CALCULATION; DRUG CLEARANCE; DRUG MONITORING; DRUG SOLUBILITY; HUMAN; KIDNEY FUNCTION; LETTER; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL;

ANTICOAGULANTS; BENZIMIDAZOLES; HUMANS; PRACTICE GUIDELINES AS TOPIC; PYRIDINES;

EID: 84888024331     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12144     Document Type: Letter

References (7)

1. Posner J,. Optimizing the dose of dabigatran etexilate. Br J Clin Pharmacol 2012; 74: 741-743.
2. Trocõniz IF, Tillmann C, Liesenfeld KH, Schäfer HG, Stangier J,. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J Clin Pharmacol 2007; 47: 371-382.
3. Lane S, Al-Zubiedi S, Hatch E, Matthews I, Jorgensen AL, Deloukas P, Daly AK, Park BK, Aarons L, Ogungbenro K, Kamali F, Hughes D, Pirmohamed M,. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol 2012; 73: 66-76.
4. Hamberg AK, Dahl ML, Barban M, Scordo MG, Wadelius M, Pengo V, Padrini R, Jonsson EN,. A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther 2007; 81: 529-538.
5. Duffull SB,. Is the ideal anticoagulant a myth? Expert Rev Clin Pharmacol 2012; 5: 231-236.
6. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W,. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386-399.
7. Duffull SB, Wright DFB, Al-Sallami HS, Zufferey PJ, Faed JM,. Dabigatran: rational dose individualisation and monitoring guidance is needed. N Z Med J 2012; 125: 148-154.